- Home
- MHH vs IFRX Comparison
MHH vs IFRX Comparison
Compare MHH & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHH
- IFRX
- Stock Information
- Founded
- MHH 1986
- IFRX 2007
- Country
- MHH United States
- IFRX Germany
- Employees
- MHH N/A
- IFRX N/A
- Industry
- MHH Professional Services
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- MHH Consumer Discretionary
- IFRX Health Care
- Exchange
- MHH Nasdaq
- IFRX Nasdaq
- Market Cap
- MHH 86.6M
- IFRX 86.0M
- IPO Year
- MHH N/A
- IFRX 2017
- Fundamental
- Price
- MHH $7.21
- IFRX $1.25
- Analyst Decision
- MHH
- IFRX Strong Buy
- Analyst Count
- MHH 0
- IFRX 5
- Target Price
- MHH N/A
- IFRX $7.40
- AVG Volume (30 Days)
- MHH 10.7K
- IFRX 716.4K
- Earning Date
- MHH 11-12-2025
- IFRX 11-07-2025
- Dividend Yield
- MHH N/A
- IFRX N/A
- EPS Growth
- MHH N/A
- IFRX N/A
- EPS
- MHH 0.07
- IFRX N/A
- Revenue
- MHH $200,000,000.00
- IFRX $191,224.00
- Revenue This Year
- MHH N/A
- IFRX N/A
- Revenue Next Year
- MHH $3.78
- IFRX $1,216.24
- P/E Ratio
- MHH $95.76
- IFRX N/A
- Revenue Growth
- MHH 5.16
- IFRX 54.36
- 52 Week Low
- MHH $6.20
- IFRX $0.71
- 52 Week High
- MHH $16.00
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- MHH 51.94
- IFRX 46.11
- Support Level
- MHH $6.76
- IFRX $1.30
- Resistance Level
- MHH $7.39
- IFRX $1.48
- Average True Range (ATR)
- MHH 0.41
- IFRX 0.15
- MACD
- MHH 0.03
- IFRX -0.02
- Stochastic Oscillator
- MHH 57.80
- IFRX 13.64
About MHH Mastech Digital Inc
Mastech Digital Inc is a provider of Digital Transformation IT Services. The Company offers data & analytics solutions & IT staffing services for both digital & mainstream technologies. The Group has two segments. Its Data & Analytics Services segment delivers specialized data management, data engineering, customer experience consulting, data analytics & cloud services to customers globally. IT Staffing Services segment combines technical expertise with business process experience to deliver a broad range of services in digital & mainstream technologies. The company derives a majority of its revenue from IT staffing services. Geographically, the majority of revenue is generated from the United States.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.